Your San Diego Biotech & Startup Financial Planner

If you work in biotech in San Diego, your financial life is probably more complex than it looks on paper.

If we were sitting down together over coffee in La Jolla or near Torrey Pines, you’d probably tell me something like this: “I make a strong income. My equity keeps growing. But honestly, I’m not totally sure I’m handling it the right way.” And that would make a lot of sense. Because in the current biotech and startup economy of San Diego, I’d like to guess that, as a financial planner, most of your wealth isn’t coming from salary but coming from equity.

RSUs. ISOs. NSOs. Stock grants you earned years ago that are finally starting to vest.

And with that comes a very California-specific challenge: You’re building wealth in one of the highest tax environments in the country.

The part most high earners don’t feel until it’s too late

What I see often with biotech executives is not a lack of income, it’s a lack of coordination. You might have RSUs vesting quarterly. Maybe you exercised options last year. Maybe you’re sitting on a concentrated position that has grown faster than expected. And then tax season arrives… and it feels like you’re giving away more than you anticipated, reacting to the income versus planning for success.

That’s usually when the questions start shifting from “How am I doing?” to: “What am I actually keeping?” That’s the real planning gap.

Equity compensation is where most of your financial story is being written

In biotech, your compensation package is rarely simple; it’s layered. RSUs show up as income when they vest, whether you sell them or not. ISOs can create opportunity but also trigger AMT exposure if the timing isn’t handled carefully. NSOs add another layer of tax timing decisions.

And if you’re at a company like Thermo Fisher Scientific, Illumina, Dexcom, or Neurocrine Biosciences, you may be sitting on a position that represents a significant portion of your net worth and that’s where things get tricky.

Because what feels like success on a spreadsheet can quietly become a risk in your portfolio if too much of your wealth is tied to one company.

At some point, the questions stop being about income and start being about freedom to live the San Diego lifestyle you signed up for.

Most of the executives I work with eventually start asking very similar questions.

These are not hypothetical questions. They usually show up right after a liquidity event, a major RSU vesting cycle, or a period where life just starts feeling… more financially real.

The transition nobody prepares you for: life after liquidity

A lot of wealth in biotech arrives in concentrated moments.

1. An IPO.
2. A secondary sale.
3. A long-awaited acquisition.
4. A buildup of RSUs that finally unlock.

And suddenly, your financial situation changes faster than your plan does.

This is often where people unintentionally fall into the same pattern: they diversify too slowly, or not at all. They hold onto concentrated stock longer than intended. Or they realize too late how large the tax impact really is. That’s not a knowledge problem, it’s a timing problem. And timing is everything here.

The goal isn’t complexity in your strategy, it’s confidence

When I work with biotech and startup executives in San Diego, the conversation usually shifts toward simplifying something that feels complicated.

We look at how RSUs are being taxed as they vest. We evaluate ISO exercise timing and whether AMT exposure is being managed intentionally. We map out whether concentrated stock is actually aligned with long-term goals or just inertia.

And then we start layering in strategy:

Not as isolated tactics but as one coordinated plan.

Because at this level, the real question is: are you in control of your financial timeline?

Most biotech executives in San Diego don’t need more complexity.

They need confident planning around three things:

1. What they actually own.
2. What it will cost them in taxes over time.
3. What freedom looks like if they stop optimizing for income alone.

A financial advisor approach to biotech wealth planning

At Your Dedicated Fiduciary, the goal isn’t to sell you products or react to one piece of your financial life at a time. It’s to bring structure to the entire picture: your equity compensation, your tax situation, your investment strategy, and your long-term planning goals.

Because in biotech, your financial life doesn’t move in straight lines. It moves in vesting cycles, liquidity events, and career transitions.Your planning should reflect that reality.

If this feels familiar, you’re probably exactly who this is for

If you’re working in San Diego biotech and you’ve ever looked at your equity comp and thought, “I know this is valuable, but I’m not sure I’m handling it correctly,” that’s usually the right moment to start tightening the strategy. Not because something is wrong but because things are starting to matter more.

Explore the most pressing financial planning questions from San Diego’s UHNW and HNW individuals.

San Diego offers diverse investment opportunities, including real estate, tech startups, and sustainable ventures. A trusted financial planner at Your Dedicated Fiduciary can help identify the best options for your portfolio.

Working with an expert financial planner at Your Dedicated Fiduciary can help structure your charitable contributions to maximize impact and align with your personal values.

Disclosures:

Your Dedicated Fiduciary does not provide legal or tax advice. You should consult a legal or tax professional regarding your individual situation.

Diversification does not assure a profit or protect against loss in declining markets, and diversification cannot guarantee that any objective or goal will be achieved.

Roth conversions involve transferring funds from a pre-tax retirement account to a Roth account, triggering current income taxes on the converted amount in exchange for potential tax-free growth and withdrawals later.